0.76
+0.0327(+4.50%)
Currency In USD
| Previous Close | 0.73 |
| Open | 0.72 |
| Day High | 0.8 |
| Day Low | 0.72 |
| 52-Week High | 3.73 |
| 52-Week Low | 0.62 |
| Volume | 3.28M |
| Average Volume | 4.94M |
| Market Cap | 274.77M |
| PE | -1.07 |
| EPS | -0.71 |
| Moving Average 50 Days | 0.79 |
| Moving Average 200 Days | 1.49 |
| Change | 0.03 |
If you invested $1000 in Lexicon Pharmaceuticals, Inc. (LXRX) 10 years ago, it would be worth $116.76 as of February 05, 2025 at a share price of $0.76. Whereas If you bought $1000 worth of Lexicon Pharmaceuticals, Inc. (LXRX) shares 5 years ago, it would be worth $229.64 as of February 05, 2025 at a share price of $0.76.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
GlobeNewswire Inc.
Jan 21, 2025 1:00 PM GMT
Event will feature insights on LX9211, Lexicon’s novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNPTHE WOODLANDS, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today
Lexicon Appoints Scott Coiante as Chief Financial Officer
GlobeNewswire Inc.
Jan 02, 2025 1:00 PM GMT
THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025. Mr. Coiant
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
GlobeNewswire Inc.
Dec 20, 2024 9:30 PM GMT
Confirms Previously Disclosed and Anticipated FDA DecisionTHE WOODLANDS, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and D